[go: up one dir, main page]

PE20080150A1 - Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) - Google Patents

Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)

Info

Publication number
PE20080150A1
PE20080150A1 PE2007000677A PE2007000677A PE20080150A1 PE 20080150 A1 PE20080150 A1 PE 20080150A1 PE 2007000677 A PE2007000677 A PE 2007000677A PE 2007000677 A PE2007000677 A PE 2007000677A PE 20080150 A1 PE20080150 A1 PE 20080150A1
Authority
PE
Peru
Prior art keywords
aril
mch
antagonists
receptor
halo
Prior art date
Application number
PE2007000677A
Other languages
English (en)
Inventor
Manuel Jesus Alcazar-Vaca
Jacqueline Macritchie
Jose Ignacio Andres-Gil
Santamarina Julen Oyarzabal
Frank Matthias Dautzenberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080150A1 publication Critical patent/PE20080150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIDINONA N-ARIL Y N-HETEROARIL SUSTITUIDOS DE FORMULA (I) DONDE A ES FENILO O PIRIDINILO; R1 Y R2 SON CADA UNO H, ALQUILO(C1-C3), ALQUILCARBONILO(C1-C3), ALQUILOXI(C1-C3)-ALQUILO(C1-C3), ENTRE OTROS; R3 ES H, HALO, CN, OH, OXO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, HALO, CN, OH, AMINO, ENTRE OTROS; k Y l SON CADA UNO DE 0 A 4; m ES DE 0 A 3; Y1 E Y3 SON CADA UNO UN ENLACE SIMPLE, NR7, O, S, SO O SO2, DONDE R7 ES H O ALQUILO(C1-C3); Y2 ES UN HIDROCARBURO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALO, CN, OH, AMINO, TIO, ENTRE OTROS; B ES UN ANILLO DE 6 MIEMBROS QUE TIENE HASTA 3 ATOMOS DE N OPCIONALMENTE SUSTITUIDO CON HALO, CN, OH, OXO, TIO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA HORMONA CONCENTRADORA DE MELANINA (MCH) SIENDO UTILES EN EL TRATAMIENTO DE ANSIEDAD, DEPRESION, PSICOSIS
PE2007000677A 2006-06-02 2007-05-31 Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) PE20080150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114917 2006-06-02
EP06123263 2006-10-31

Publications (1)

Publication Number Publication Date
PE20080150A1 true PE20080150A1 (es) 2008-04-11

Family

ID=38266244

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000677A PE20080150A1 (es) 2006-06-02 2007-05-31 Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)

Country Status (5)

Country Link
AR (1) AR061163A1 (es)
PE (1) PE20080150A1 (es)
TW (1) TW200811146A (es)
UY (1) UY30378A1 (es)
WO (1) WO2007141200A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041090A1 (en) * 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
EP2406233B1 (en) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US20120071459A1 (en) * 2009-06-03 2012-03-22 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
US20120083489A1 (en) * 2009-06-03 2012-04-05 Christensen Iv Siegfried Benjamin Bis-pyridylpyridones as melanin-concentrating hormone receptor antagonists
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US20120316200A1 (en) * 2010-04-12 2012-12-13 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011127643A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
ES2873029T3 (es) 2010-12-06 2021-11-03 Aclaris Therapeutics Inc Compuestos de piridinona-piridinilo sustituidos
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2013149362A1 (en) * 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
EP2875001B1 (en) 2012-07-18 2019-01-09 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
HRP20210813T1 (hr) 2013-06-07 2021-06-25 Aclaris Therapeutics, Inc. Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
CN107698499A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
CN116023327A (zh) * 2016-08-08 2023-04-28 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
WO2021142395A1 (en) * 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
CN115666566A (zh) 2020-03-27 2023-01-31 阿克拉瑞斯治疗股份有限公司 用于免疫病况的治疗的mk2途径抑制剂的口服组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN1930126A (zh) * 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
WO2007024004A1 (ja) * 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体

Also Published As

Publication number Publication date
WO2007141200A1 (en) 2007-12-13
UY30378A1 (es) 2008-01-02
AR061163A1 (es) 2008-08-06
TW200811146A (en) 2008-03-01
WO2007141200A8 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20120135A1 (es) Piperidinas sustituidas como antagonistas de ccr3
AR061644A1 (es) Derivados de benzofurano
PE20081887A1 (es) Nuevo compuesto de adenina
PE20080855A1 (es) Derivados de pirazina-2-carboxamida
PE20130155A1 (es) Derivados de ariletinilo
PE20090775A1 (es) Nuevos derivados de biarilo
AR064355A1 (es) Herbicidas derivados de isoxazol
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20080889A1 (es) Aminometil-4-imidazoles
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5

Legal Events

Date Code Title Description
FC Refusal